Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
Ella Day | July 3, 2025 | News story | Research and Development | Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to a standard 225IU/day dose of follitropin alfa in women undergoing ovarian stimulation for fertility treatments: in vitro fertilisation or intracytoplasmic sperm injection. This reinforces the clinical evidence base for follitropin delta, the only recombinant follicle-stimulating hormone with support for both algorithm-based and conventional dosing approaches.
The new data was presented at the European Society of Human Reproduction and Embryology Congress taking place in Paris in France from 29 June to 2 July. It has also been published in Human Reproduction.
The ADAPT-1 trial enrolled 300 women aged 18 to 40 years old to evaluate the number of oocytes retrieved as the primary endpoint. Results showed both treatment arms achieved a mean of 9.9 oocytes retrieved, with clinical pregnancy rates of 31.6% for follitropin delta and 31.0% for follitropin alfa. Drug exposure was slightly lower in the delta group, and early ovarian hyperstimulation syndrome (OHSS) rates remained low across both groups, 2.5% and 3% respectively, with no treatment cancellations due to excessive response.
Follitropin delta is currently approved with an individualised dosing algorithm based on anti-Müllerian hormone levels and body weight, designed to optimise ovarian response while minimising OHSS risk. The ADAPT-1 findings support its safe and effective use in a conventional fixed-dose regimen.
“This data provides confidence and expand our understanding for dosing in follitropin delta,” said Andrea Bernabeu, principal investigator of the study. Ferring intends to engage regulators for broader clinical application.
Ella Day
3/7/25
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
